# Multi-biomarker assessment to better understand clinical dementia symptoms 17 Feb 26 blog # Multi-biomarker assessment to better understand clinical dementia symptoms Robin Wolz Alzheimers Disease Bio-Hermes [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/blog/multi-biomarker-assessment-to-better-understand-clinical-dementia-symptoms/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/blog/multi-biomarker-assessment-to-better-understand-clinical-dementia-symptoms/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/blog/multi-biomarker-assessment-to-better-understand-clinical-dementia-symptoms/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/blog/multi-biomarker-assessment-to-better-understand-clinical-dementia-symptoms/) ![Multi biomarker assessment to better understand clinical dementia symptoms](/assets/blog-images/Multi-biomarker-assessment-to-better-understand-clinical-dementia-symptoms__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)Many patients with mild cognitive impairment (MCI) or early Alzheimer’s disease meet clinical criteria for AD but when scanned using PET do not show amyloid pathology (the accumulation of misfolded amyloid proteins in tissues known to cause brain disfunction). In a new paper from the Bio-Hermes Study, led by the Global Alzheimer’s Platform (GAP) in collaboration with partners including IXICO, we explored what blood-based biomarkers can (and can’t) tell us about this important group. Across nearly 300 cognitively impaired, amyloid-negative participants, neurofilament light (NfL) consistently differentiated impairment from cognitively normal controls—pointing to underlying neurodegeneration even in the absence of amyloid or tau signals. In contrast, a wide range of novel proteomic and inflammatory markers showed limited discriminatory value. The message is clear: amyloid-negative cognitive impairment is biologically diverse and highly variable, and today’s biomarker toolbox is still incomplete to account for such heterogeneity. That’s why Bio-Hermes 2 is now extending this work with deeper MRI-based and vascular phenotyping to better understand non-amyloid pathways that may drive neurodegeneration and cognitive decline. It's an exciting area of research and IXICO is proud to be part of this collaborative effort with GAP and Bio-Hermes. Find out more about this paper [here](/news-and-resources/publications/biomarkers-in-patients-with-clinical-signs-of-mild-cognitive-impairment-or-mild-alzheimers-disease-but-without-amyloid-deposits-on-positron-emission-tomography/) [ Back to Blog ](/news-and-resources/blog/) ### Recents ![Beyond Diagnosis: 8 MRI and PET Biomarkers Shaping Alzheimer's Clinical Trials](/assets/blog-images/Alzheimers-biomarkers__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 29 Sep 26 blog [Beyond Diagnosis: 8 MRI and PET Biomarkers Shaping Alzheimer's Clinical Trials](/news-and-resources/blog/pet-mri-biomarkers-alzheimers-clinical-trials/) [White matter hyperintensities: A precision neurology tool for Alzheimer’s patient stratification and improved trial sensitivity? ](/news-and-resources/blog/white-matter-hyperintensities-a-precision-neurology-tool-for-alzheimers-patient-stratification-and-improved-trial-sensitivity/) [Neuromelanin MRI: An Early, Longitudinal Biomarker for Parkinson’s Disease](/news-and-resources/blog/neuromelanin-mri-an-early-longitudinal-biomarker-for-parkinsons-disease/) [From Information to Intelligence: New Platform Identity Explained](/news-and-resources/blog/from-information-to-intelligence-bram-goodren-ceo-of-ixico-explains-the-new-identity-of-the-ixi-platform-and-why-it-matters/) [Advancing HD Clinical Trials with Automated Imaging: What the Latest Research Shows](/news-and-resources/blog/advancing-hd-clinical-trials-with-automated-imaging-what-the-latest-research-shows/) ### Library [November 2026](/news-and-resources/blog/archive/2026/11/) [October 2026](/news-and-resources/blog/archive/2026/10/) [September 2026](/news-and-resources/blog/archive/2026/09/) [July 2026](/news-and-resources/blog/archive/2026/07/) [June 2026](/news-and-resources/blog/archive/2026/06/) [May 2026](/news-and-resources/blog/archive/2026/05/) [April 2026](/news-and-resources/blog/archive/2026/04/) [March 2026](/news-and-resources/blog/archive/2026/03/) [February 2026](/news-and-resources/blog/archive/2026/02/) [January 2026](/news-and-resources/blog/archive/2026/01/) [2025](/news-and-resources/blog/archive/2025/) [2024](/news-and-resources/blog/archive/2024/) [2023](/news-and-resources/blog/archive/2023/) [2022](/news-and-resources/blog/archive/2022/) [2021](/news-and-resources/blog/archive/2021/) [2020](/news-and-resources/blog/archive/2020/) [2019](/news-and-resources/blog/archive/2019/)